This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A 35-year-old man developed progressive memory problems and personality changes over the course of 6 months. This amnesia culminated in overt functional impairment as he began getting lost in familiar places and paid his rent multiple times in one day. He then displayed increased aggression and was admitted to hospital after assaulting a family member.
Footnotes
↵* These authors contributed equally to this work.
Author contributions: Drs. Adler, Mat, and Merwick drafted the manuscript. Drs. Chadwick, Gullo, and Tubridy were involved in critical revision of the manuscript. All the aforementioned authors were involved in the diagnosis and treatment of the patient. Dr. Dalmau performed the CSF analysis for mGluR5 antibodies, and was involved in critical revision of the manuscript.
Study funding: No targeted funding reported.
Disclosure: A. Mat reports no disclosures. H. Adler has received travel grants from Biogen Idec. A. Merwick reports unrestricted educational grants toward travel/accommodation costs for attendance at conferences from Boehringer Ingelheim, Pfizer Healthcare, Lunbeck, and Biogen Idec. G. Chadwick and G. Gullo report no disclosures. J. Dalmau is Professor at Institució Catalana de Recerca i Estudis Avançats (ICREA) in IDIBAPS/Hospital Clínic, Barcelona; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc., for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award. N. Tubridy is an advisory board member for Novartis and has received travel grants from Bayer Schering, Novartis, and Sanofi. Go to Neurology.org for full disclosures.
- Received July 9, 2012.
- Accepted November 27, 2012.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard